# Successful Treatment of Netherton Syndrome With Combination of Secukinumab and Dupilumab

> **NCT07151508** · — · COMPLETED · sponsor: **Federal Research Institute of Pediatric Hematology, Oncology and Immunology** · enrollment: 15 (actual)

## Conditions studied

- Neterton Syndrome

## Interventions

- **DEVICE:** Secukinumab was administered in a weight-adapted dosing regimen ? Dupilumab was administered at a dose dependent on the patient's weight and age

## Key facts

- **NCT ID:** NCT07151508
- **Lead sponsor:** Federal Research Institute of Pediatric Hematology, Oncology and Immunology
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2023-12-19
- **Primary completion:** 2024-12-25
- **Final completion:** 2025-01-10
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2025-09-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07151508

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07151508, "Successful Treatment of Netherton Syndrome With Combination of Secukinumab and Dupilumab". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07151508. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*